We are live on ! Find out more
AEON.WS

AEON Biopharma Inc
AEON.WS

Delisted

AEON.WS was delisted on the 26th of April, 2024.

Back to rankings

48 hedge funds and large institutions have $7.84M invested in AEON Biopharma Inc in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 2

23% more funds holding

Funds holding: 39 → 48 (+9)

18% more capital invested

Capital invested by funds: $6.66M → $7.84M (+$1.18M)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
48
Holders Change
+9
Holders Change %
+23.08%
% of All Funds
0.84%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
1
Reduced
2
Closed
2
Calls
$1.07M
Puts
–
Net Calls
+$1.07M
Net Calls Change
-$19K

Top Buyers

Rank Fund Capital Flow
1
ECP
Empyrean Capital Partners
California
+$342K
2
SCM
Shaolin Capital Management
Florida
+$199K
3
Citadel Advisors
Citadel Advisors
Florida
+$120K
4
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$119K
5
CL
CSS LLC
Illinois
+$87.9K

Top Sellers

Rank Fund Capital Flow
1
LA
Linden Advisors
New York
-$204K
2
WAM
Wolverine Asset Management
Illinois
-$4.39K
3
CAC
Cowen and Company
New York
-$3.09K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCC
26
Spring Creek Capital
Kansas
$46K – – –
Balyasny Asset Management
27
Balyasny Asset Management
Illinois
$37K – – –
GPCM
28
Granite Point Capital Management
Massachusetts
$37K – – –
AA
29
AQR Arbitrage
Connecticut
$31K – – –
WAM
30
Wolverine Asset Management
Illinois
$29K -$4.39K -6,000 -11%
AR
31
Advisory Research
Illinois
$29K – – –
FCM
32
Farallon Capital Management
California
$29K – – –
FIG
33
Fortress Investment Group
New York
$29K – – –
SC
34
Sculptor Capital
New York
$29K – – –
DCM
35
Dupont Capital Management
Delaware
$27K – – –
D.E. Shaw & Co
36
D.E. Shaw & Co
New York
$18K – – –
MCM
37
Moore Capital Management
New York
$18K – – –
ESCM
38
Echo Street Capital Management
New York
$18K +$24.4K +33,333 New
CAC
39
Cowen and Company
New York
$12K -$3.09K -4,218 -17%
NAM
40
Nexpoint Asset Management
Texas
$8K +$9.77K +13,333 New
RA
41
Ramius Advisors
New York
$7K +$9.08K +12,400 New
RCM
42
Rivernorth Capital Management
Florida
$7K +$9.77K +13,332 New
CC
43
Centiva Capital
New York
$6K – – –
EC
44
EJF Capital
Virginia
$6K – – –
AA
45
Ancora Advisors
Ohio
$3K – – –
Qube Research & Technologies (QRT)
46
Qube Research & Technologies (QRT)
United Kingdom
$2K – – –
UBS Group
47
UBS Group
Switzerland
$2K – – –
6CM
48
683 Capital Management
New York
$2K +$2.44K +3,333 New
LA
49
Linden Advisors
New York
– -$204K -200,000 Closed
1
2

AEON.WS Hedge Fund Activity: Q3 2021 in Review

48 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q3 2021, worth a combined $7.84M — up 18% from $6.66M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new AEON.WS positions and 2 closed out — a net gain of 9 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Empyrean Capital Partners, opening a new position worth an estimated $342K. The largest seller was Linden Advisors, exiting entirely with an estimated $204K sold.

  • 48 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q3 2021, up from 39 in Q2 2021.
  • Funds reported $7.84M of AEON Biopharma Inc stock for Q3 2021, up 18% quarter-over-quarter.
  • 11 funds opened new AEON Biopharma Inc positions in Q3 2021 and 2 closed out, a net change of +9 holders.
  • The largest AEON Biopharma Inc buyer in Q3 2021 was Empyrean Capital Partners, an estimated $342K added.
  • The largest AEON Biopharma Inc seller in Q3 2021 was Linden Advisors, an estimated $204K sold.

Based on aggregated 13F filings for Q3 2021.